Table 1 Characteristics of included studies
Study | Country | Sample number (PE/NE) | Histology (intestinal/diffuse/mixed) | Detecting method | Cut-off value | Positive site | Investigating fields | Estimates | Follow-up (maximum) | NOS score | |
|---|---|---|---|---|---|---|---|---|---|---|---|
CP features | Prognosis | ||||||||||
Bodoor et al. [20] | Jordan | 87(18/69) | 49/38/– | IHC | 20% staining | Cytoplasm,Nucleus | √ | √ | OR,HR | 88 months | 7 |
Chid et al. [28] | China | 50(39/11) | – | IHC | 5% staining | Cytoplasm,Nucleus | √ |  | OR | – | 6 |
Ando et al. [21] | Japan | 182(137/45) | – | IHC | 70% staining | Cytoplasm | √ | √ | OR,HR | NR | 7 |
Lee et al. [22] | Korea | 172(50/122) | 89/83/– | IHC | 10% staining | Cytoplasm,Nucleus | √ | √ | OR,HR | NR | 8 |
Kang et al. [23] | Korea | 458(155/303) | 239/219/– | IHC | 50% staining | Cytoplasm | √ | √ | OR,HR | 83.8 months | 8 |
Pfister et al. [24] | Germany | 19(7/12) | – | Flow Cytometry | 10% staining | NR | √ | √ | OR,HR | 50.4 months | 6 |
Isomoto et al. [25] | Japan | 81(55/26) | – | IHC | 10% staining | Cytoplasm,Nucleus | √ | √ | OR,HR | NR | 8 |
Canöz et al. [26] | Turkey | 94(87/7) | 56/21/17 | IHC | 5% staining | Cytoplasm | √ |  | OR | – | 7 |
Maehara et al. [27] | Japan | 164(82/82) | – | IHC | 19% staining | Cytoplasm,Nucleus | √ | √ | OR,HR | NR | 8 |